Home › Autoimmune Diseases
Autoimmune Diseases clinical trials recruiting in the U.S.
76 studies for Autoimmune Diseases are recruiting participants at sites across the United States.
Autoimmune diseases are where your immune system attacks healthy cells in your body by mistake. Learn about the symptoms, tests, and treatments.
Cities with the most studies
- Houston, TX21 studies
- Washington, DC19 studies
- New York City, NY19 studies
- Philadelphia, PA16 studies
- Durham, NC15 studies
- Boston, MA13 studies
- Los Angeles, CA12 studies
- Chicago, IL12 studies
- Dallas, TX9 studies
- Portland, OR8 studies
- Cleveland, OH8 studies
- Atlanta, GA8 studies
- Milwaukee, WI8 studies
- Pittsburgh, PA7 studies
- Cedar Rapids, IA7 studies
- Seattle, WA7 studies
- Orange, CA7 studies
- San Francisco, CA7 studies
- The Bronx, NY6 studies
- Louisville, KY6 studies
- Mountain View, CA6 studies
- Kansas City, KS6 studies
- Salt Lake City, UT6 studies
- Jacksonville, FL6 studies
- Baltimore, MD6 studies
- Rochester, MN6 studies
- Ann Arbor, MI6 studies
- Miami, FL6 studies
- Memphis, TN6 studies
- San Diego, CA5 studies
- Aurora, CO5 studies
- Sacramento, CA5 studies
- New Haven, CT5 studies
- Nashville, TN5 studies
- Indianapolis, IN4 studies
- Greenville, NC4 studies
- Kansas City, MO4 studies
- Phoenix, AZ4 studies
- Charleston, SC4 studies
- Worcester, MA4 studies
By state
- Alabama5 studies
- Arizona6 studies
- Arkansas3 studies
- California27 studies
- Colorado8 studies
- Connecticut5 studies
- District of Columbia6 studies
- Florida20 studies
- Georgia10 studies
- Illinois14 studies
- Indiana4 studies
- Iowa7 studies
- Kansas7 studies
- Kentucky8 studies
- Maryland21 studies
- Massachusetts16 studies
- Michigan9 studies
- Minnesota9 studies
- Missouri7 studies
- Nebraska3 studies
- New Jersey5 studies
- New York24 studies
- North Carolina18 studies
- Ohio13 studies
- Oklahoma4 studies
- Oregon9 studies
- Pennsylvania21 studies
- South Carolina4 studies
- Tennessee10 studies
- Texas22 studies
- Utah7 studies
- Virginia6 studies
- Washington8 studies
- Wisconsin8 studies
Recently updated studies
Environmental Risk Factors for the Anti-synthetase Syndrome
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 100 · All sexes · Updated Sep 28, 2026 · NCT01276470Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
RecruitingPhase 2Healthy volunteers welcome
Ages 4 to 75 · All sexes · Updated Sep 28, 2026 · NCT02579967Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07621809Natural History of Bronchiectasis
RecruitingObservational studyHealthy volunteers welcome
Ages 5 to 100 · All sexes · Updated Sep 28, 2026 · NCT00943514NIAID Centralized Sequencing Protocol
RecruitingObservational studyHealthy volunteers welcome
1 Day – 100 Years · All sexes · Updated Sep 28, 2026 · NCT03206099Secukinumab Open Label Roll-over Extension Protocol
RecruitingPhase 4
Ages 6 to 100 · All sexes · Updated Sep 28, 2026 · NCT04638647Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Sep 28, 2026 · NCT04097561Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
RecruitingPhase 2
Ages 4 to 69 · All sexes · Updated Sep 28, 2026 · NCT04339777A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Sep 25, 2026 · NCT07541287Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
RecruitingObservational study
1 Month – 100 Years · All sexes · Updated Sep 24, 2026 · NCT00246857Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
RecruitingObservational study
Up to age 99 · All sexes · Updated Sep 24, 2026 · NCT00001350Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
RecruitingPhase 2
Ages 18 to 90 · All sexes · Updated Sep 22, 2026 · NCT00977977Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 21, 2026 · NCT07513181A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06722235RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RecruitingPhase 2/3
Ages 6 to 75 · All sexes · Updated Sep 17, 2026 · NCT06154252A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
RecruitingPhase 2
Ages 16 to 70 · All sexes · Updated Sep 17, 2026 · NCT07328581Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07103746Daratumumab in Primary Antiphospholipid Syndrome
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Sep 16, 2026 · NCT05671757METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)
RecruitingPhase 2
Ages 18 to 69 · All sexes · Updated Sep 15, 2026 · NCT07699380A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 11, 2026 · NCT07059000A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06948318PS-002 for the Treatment of IgA Nephropathy in Adults
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07182227A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06572384From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.